Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron (NASDAQ: LGVN) will report its 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026, after U.S. markets close.

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) will report its 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, with dial-in 1.877.407.0789 and conference ID 13761959. An archived replay will be available on the Events & Presentations section of Longeveron’s website.

Argus Aug 4 session 12 alerts

+1.38% close to close 3.2x rel. volume Open Argus

Details

News Market Reaction – LGVN

+3.9% Peak Tracked

-3.4% Trough Tracked

$25.28M Market Cap

On Aug 4, the first trading day after this news, LGVN closed 1.38% above the previous close. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner recorded 12 alerts for this stock that day. Relative volume reached 3.2x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 4 session.

Market Context

Tag-matched history averaged 0.83% across 2 events, adding a mixed precedent to this earnings-date a...

Analysis

Tag-matched history averaged 0.83% across 2 events, adding a mixed precedent to this earnings-date announcement. Low short positioning and absent peer headlines provide context, while financial outcomes are not yet reported.

Key Figures

Reporting period: 2026 second quarter Results date: August 12, 2026 Conference call time: 4:30 p.m. ET +2 more

Reporting period

2026 second quarter

Financial results scheduled for August 12, 2026

Results date

August 12, 2026

After U.S. financial markets close

Conference call time

4:30 p.m. ET

August 12, 2026

Conference call number

1.877.407.0789

Conference call access

Conference ID

13761959

Conference call access

Previous Conferences,earnings date Reports

2 past events · Latest: May 05

Same Type 2 events

1. May 05

   Earnings date

   24h Move

   +2.1%

   Scheduled first-quarter results and conference call after market close

2. Mar 12

   Earnings date

   24h Move

   -0.4%

   Scheduled full-year results and conference call after market close

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

regenerative medicine, cellular therapies

2 terms

regenerative medicine medical

"a clinical stage regenerative medicine biotechnology company"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

cellular therapies medical

"developing cellular therapies for life-threatening and chronic aging-related conditions"

Cellular therapies use living cells as the medicine—by modifying, growing, or transplanting a patient’s own cells or donated cells to treat disease, stimulate repair, or replace damaged tissue. They matter to investors because they can deliver dramatic clinical benefits and command high prices, but also carry significant risks and costs around clinical trials, regulatory approval, and complex manufacturing; think of them as custom-made medicines rather than off-the-shelf pills.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

Conference Call Number:	1.877.407.0789
Conference ID:	13761959
Call me™ Feature:	Click Here
Webcast:	Click Here

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Longeveron (NASDAQ: LGVN) report its 2026 Q2 financial results?

Longeveron will report its 2026 second quarter financial results on Wednesday, August 12, 2026, after U.S. markets close. According to Longeveron, the release will be accompanied by a conference call and webcast the same day at 4:30 p.m. ET.

What time is Longeveron’s 2026 Q2 earnings conference call on August 12, 2026?

Longeveron’s 2026 Q2 conference call is scheduled for 4:30 p.m. ET on August 12, 2026. According to Longeveron, the call will follow the financial results release after market close and include a business update and webcast access.

How can investors join Longeveron’s (LGVN) 2026 Q2 earnings call?

Investors can join Longeveron’s 2026 Q2 earnings call by dialing 1.877.407.0789 and using conference ID 13761959. According to Longeveron, a webcast and a Call me™ feature are also available via the company’s online access links.

Will there be a replay of Longeveron’s August 12, 2026 LGVN earnings webcast?

Yes, a replay of Longeveron’s August 12, 2026 webcast will be available. According to Longeveron, the archived replay will be posted in the “Events & Presentations” section of the company’s website following the live conference call.

Where can I find the webcast link for Longeveron’s (LGVN) 2026 Q2 results call?

The webcast link for Longeveron’s 2026 Q2 results call is provided as a “Click Here” access option. According to Longeveron, this webcast can be accessed online, with replay later available on the company’s Events & Presentations webpage.